Chiesi USA Appoints VP of Medical Affairs to Support Continued Growth
March 29, 2021 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has...
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
March 22, 2021 09:00 ET
|
Chiesi USA, Inc.
New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a Certified B Corporation™ businessPatients’ experiences and perception of Chiesi at the heart of...
Chiesi Group announces performance growth in 2020
March 18, 2021 09:00 ET
|
Chiesi USA, Inc.
Chiesi Group currently employs 6,389 people worldwide, 2,119 of whom are in Italy, and has a turnover of €2.229 billion.Chiesi’s business comprises 30 affiliates, seven research centers, three...
Chiesi USA, Inc. announces Commercial Availability of Bronchitol® (mannitol) inhalation powder for improvement in pulmonary function in adult patients with cystic fibrosis
March 17, 2021 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., March 17, 2021 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the...
Chiesi USA Announces Sponsorship of ASHP Foundation’s Pharmacy Leadership Scholars Program
March 16, 2021 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., March 16, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced...
Chiesi USA donates more than $800,000 in 2020
March 01, 2021 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group),...
Chiesi Group receives the European Marketing authorization for the extrafine triple-combination therapy for the treatment of moderate to severe asthma
February 01, 2021 09:00 ET
|
Chiesi USA, Inc.
It is the first extrafine fixed triple combination therapy in a single inhaler to be approved for use in asthma patients. This follows the 2017 approval of this therapeutic option for the treatment of...
Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2021
January 25, 2021 09:30 ET
|
Chiesi USA, Inc.
CARY, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced...
Chiesi USA Announces Key Promotions to Business Unit Leads
January 21, 2021 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has...
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease
December 23, 2020 18:15 ET
|
Chiesi USA, Inc.
- Program grants access to investigational therapy for Fabry disease patients in the United States who cannot be adequately treated with currently available FDA-approved drugs - BOSTON, Dec. 23,...